CCDC184

Across TCGA pan-cancer cohorts, CCDC184 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated CCDC184 data layer compared with 3 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher CCDC184 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC184 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LIHC show a favorable association.

MESO, UVM, and BLCA are the cancer types where CCDC184 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.271	0.497	<.001	105	view →
UVM	OS	Median	All	0.402	0.829	<.001	81	view →
BLCA	OS	Tertile	All	0.433	0.779	.001	53	view →
LUAD	OS	Quartile	All	0.673	0.158	.001	43	view →
LIHC	OS	Tertile	All	0.842	0.713	.002	39	view →
ACC	DFS	Tertile	All	0.222	0.815	<.001	35	view →
KIRC	OS	Tertile	All	0.834	0.755	.008	27	view →
STAD	OS	Tertile	All	0.443	0.609	.008	15	view →
THCA	DFS	Tertile	All	0.956	0.896	.006	13	view →
BRCA	OS	Tertile	III,IV	0.887	0.773	.018	11	view →
COAD	DFS	Tertile	All	0.603	0.726	.021	10	view →
SCLC	DFS	Median	III,IV	0.338	0.968	.024	7	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

CCDC184–MESO (OS)

Open the MESO breakdown →